Dispersion of tumors throughout the body is a neoplastic process responsible for the vast majority of deaths from cancer. Despite disseminating to distant organs as malignant scouts, most tumor cells fail to remain viable after their arrival. The physiologic microenvironment of the brain must become a tumor-favorable microenvironment for successful metastatic colonization by circulating breast cancer cells. Bidirectional interplay of breast cancer cells and native brain cells in metastasis is poorly understood and rarely studied. We had the rare opportunity to investigate uncommonly available specimens of matched fresh breast-to-brain metastases tissue and derived cells from patients undergoing neurosurgical resection. We hypothesized that, to metastasize, breast cancers may escape their normative genetic constraints by accommodating and coinhabiting the neural niche. This acquisition or expression of brainlike properties by breast cancer cells could be a malignant adaptation required for brain colonization. Indeed, we found breast-to-brain metastatic tissue and cells displayed a GABAergic phenotype similar to that of neuronal cells. The GABA A receptor, GABA transporter, GABA transaminase, parvalbumin, and reelin were all highly expressed in breast cancer metastases to the brain. Proliferative advantage was conferred by the ability of breast-to-brain metastases to take up and catabolize GABA into succinate with the resultant formation of NADH as a biosynthetic source through the GABA shunt. The results suggest that breast cancers exhibit neural characteristics when occupying the brain microenvironment and co-opt GABA as an oncometabolite.
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brain metastasis | tumor microenvironment M etastases are responsible for 90% of all cancer deaths, and patients diagnosed with brain metastases have a dismal 20% probability of 1-y survival (1) (2) (3) . The brain is increasingly the first site of recurrence after treatment of stage IV advanced breast cancer, even when disease in other sites is in remission. This emerging clinical problem significantly limits the survival gains made from recent advances in systemic therapy for breast cancer (4) . Breast cancer metastasizes to the brain in ∼40% of patients who have a tumor that is HER2 + (>30% of tumor cells have complete membrane staining for the tyrosine kinase receptor erbB2) or triple negative (TN) (negative for the estrogen and progesterone receptors and have reduced expression of HER2 + ) (5). Ninety percent of patients with these breast cancer subtypes will die of metastasis to the brain (1). Currently, treatment options beyond radiotherapy and neurological surgery are limited, underscoring the need for research into the biology of these clinically recalcitrant tumors (6) .
Breast cancer patients typically develop brain metastases months to several years after their initial diagnosis (6) . This unique clinical latency occurs despite the early presence of circulating tumor cells, often detectable at the time of primary diagnosis (7) (8) (9) . These observations suggest that the final step of the metastatic cascade to colonize the brain may be the ratelimiting biological step that determines whether or not clinical progression will occur. Primary cancers, especially those of breast origin, have numerous changes in transcriptome networks that can lead to clones with additional survival gains at secondary sites (10) (11) (12) (13) (14) . We previously showed that metastatic cells have the ability to alter the cellular milieu of the brain for growth advantage (3).
γ-Aminobutyric acid (GABA) was first identified in the mammalian brain over one-half a century ago and subsequent studies have demonstrated its relevance to various medical and scientific paradigms (15) (16) (17) (18) . In addition to its role in neurotransmission, GABA can act as a trophic factor during nervous system development to influence cellular events including proliferation, migration, differentiation, synapse maturation, and cell death (19, 20) . Various cells can catabolize GABA to meet their metabolic needs. Under conditions that inhibit the tricarboxylic acid cycle, impair respiration, and enhance the accumulation of reactive oxygen intermediates, GABA can be used as an energy source for growth through a pathway known as the GABA shunt (21) . The expression of GABA in adult tissues is specific and tightly regulated. Abnormal GABA expression or GABAergic participation has been described in primary colon, gastric, ovarian, pancreatic, and breast cancers (22) .
We obtained surgical specimens of HER2 + and TN subtypes from patients undergoing neurological surgery. This offered a rare opportunity to examine the histological, cellular, and molecular features of the tumor microenvironment that cannot be recreated using highly passaged cell lines and derived xenografts. Results showed that breast-to-brain metastatic (BBM) cells overexpressed integral proteins from the GABA-related variables, including GABA transaminase (ABAT), GABA A receptor (GABA A R), glutamate decarboxylase (GAD67), GABA transporter, reelin, and parvalbumin. Brain metastases from both types of breast cancer (HER2 + , TN) metabolized GABA in vitro Significance Breast cancer patients typically develop brain metastases years after their initial diagnosis. During this clinical latency, cancer cells must evolve and adapt to the neural microenvironment to colonize. We hypothesized that breast cancer cells may assume brain-like properties to survive in the brain. Our results suggest that metastases overexpress many variables related to the γ-aminobutyric acid (GABA) and were able to proliferate by metabolizing GABA as a biosynthetic energy source. The expression of brain-like properties by breast cancer cells could be a malignant adaptation required for metastasis to the brain, which could potentially be exploited to develop new therapy for breast cancer patients.
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The authors declare no conflict of interest. and used it as biosynthetic source to enhance cell growth. The expression of GABAergic features by BBM cells demonstrates that, despite their origins in distinct and disparate germ-line tissues, cancers have the ability to adapt to and colonize new microenvironments.
Results BBM Cells Exhibit GABA-Related Variables. The tumor and brain microenvironment is a highly specialized niche determined by its tissue-specific location and cell-derived contents. Unlike tumors originating within the brain (glioblastoma multiforme), metastatic breast tumors are noninfiltrating and retain their original tissue morphology. The demarcation of the brain-tumor interface can be clearly discerned histologically or clinically on magnetic resonance imaging (Fig. 1) . In patients undergoing neurosurgical resection of BBMs, specimens from the tumor and brain interface demonstrated few healthy neurons. Metastatic breast cancer cells were juxtaposed to astrocytes expressing glial fibrillary acidic protein (GFAP) both in the peritumoral brain and tumor regions (Fig. 1) . Furthermore, these reactive astrocytes had a hypertrophic morphology comparable to the glial scars that form in response to traumatic brain injury (23) .
Resected BBM specimens were classified by their clinical subtypes (HER2 + and TN) and Bloom-Richardson pathological grade (24) . Biopsies of brain metastases revealed ductal carcinomas with high-grade Bloom-Richardson score (BRG3) (Fig.  S1 ). Low-passage cells derived from metastatic brain tumor resections maintained their original tissue morphology when grown in serum-free "brain-like" conditions and 3D Matrigel cultures ( Fig. S1 ) (25) . Within the intratumoral space in metastatic brain tissue, cells of glial origin interdigitated with the breast tumor cells (26) . Investigating the tumor cell and stromal compartments separately revealed differences in the microenvironments (12) . Staining with H&E combined with staining for GFAP (expressed in the intratumoral glial cells) and HER2 ). Cultured BBM cells organized into microcolonies with cells retaining multiple nucleoli (Fig. S1) .
Because of the abundant expression of GABA receptors and GABA in the brain microenvironment (27) , we investigated whether BBM cells had any GABAergic properties by comparing the expression of their genes and proteins to the highly passaged primary breast cancer cell lines, SkBr3 and MDA-MB-231. All GABA receptor mRNA isoforms were highly up-regulated in HER2
+ BBMs relative to HER2 + primary breast cancer cell line SkBr3 (Fig. 2A) . The expressions of 12 of 15 GABA receptor mRNA isoforms were up-regulated in TN BBM cells relative to MDA-MB-231 ( Fig. 2A and Table S1 ). GABA A R protein was expressed by both HER2 + and TN breast cancer subtypes in vitro (Fig. S3A) .
The tumor compartments of both BBM HER2 + and TN subtypes had significantly increased levels of GABA A R relative to the primary tissue tumor correlates (Fig. 2B, Fig. S3B , and Table S2 ). The fold increase was 1.46 in HER2 + cancer cells and 3.12 in TN cancer cells, relative to matched clinical subtype primary breast tissue (Fig. S3C) . A survey of the nontumor microenvironment also revealed GABA A R expression was increased in the brain region of TN BBMs relative to TN primary breast tumor stromal tissue (Fig. S3B) . Expression of GABA A Re subunit mRNA was decreased 20-fold in TN BBM cells relative to TN primary breast cancers ( Fig. 2A) , and the expression of the protein was low in both primary and metastatic tissues (Fig.  S4) . Variance between mRNA and protein level expression in BBMs could be due to differential micro-RNA-mediated silencing, proteasome degradation, or RNA turnover resulting in augmented translation (28, 29) .
The effect of exogenous GABA on the growth of BBM cells in culture was investigated next. GABA induced dose-dependent increases in cellular proliferation rates; the average EC 50 was 0.8 μM for HER2 + BBM cells (Fig. 2C ) and 0.4 μΜ for TN BBM cells (Fig. S3D ). This increase in proliferation could be mediated either by GABA A R signaling or by increased GABA metabolism. To distinguish between these two possibilities, we tested the proliferative capacity of cells with muscimol, a potent GABA mimetic selective for GABA A R that cannot be used as a metabolic resource (30, 31) . When BBM cells were cultured with muscimol, there was no change in proliferation relative to nontreated cells (Fig. 2D and Fig. S3E ), indicating that the observed growth rate of the cells treated with exogenous GABA was not mediated through GABA A R signaling.
GABA Metabolism Promotes Tumor Cell Proliferation. BBM cells may express highly specific GABA transporters that take up GABA from the brain microenvironment. HER2
+ BBM cells had elevated mRNA levels for vesicular GABA transporter (VGAT), GABA transporter 1 through 3 (GAT1-3) , and the GABA-betaine transporter (BGT) relative to HER2 + SkBr3 primary breast cancer cells. TN BBM cells had a twofold or higher increase in VGAT, GAT3, and BGT relative to TN MDA-MB-231 primary breast cancer cells (Table S2 and Fig.  S5A ). GAT1 protein was expressed by both BBM subtypes in vitro (Fig. S5B) . Staining of tissue specimens revealed the expression levels of GAT1 in HER2 + BBM, and adjacent brain tissue regions were equivalent to primary tissue. However, the expression of GABA transporter in TN BBMs and adjacent brain regions was higher relative to primary tissue regions (Fig.  S5C) . These results suggest that metastatic breast cells in the brain have acquired the ability to take up extracellular GABA.
Neurons and astrocytes express GABA transaminase (ABAT), which converts GABA to succinate, resulting in subsequent production of NADH to satisfy energy and growth requirements (32) . Accordingly, BBM cells may also use ABAT to metabolize GABA. Datasets from 357 patients show BBMs have increased ABAT expression relative to primary breast cancer (1.9-fold change, P = 0.020) and normal breast tissue (4.3-fold change, P = 4.9 × 10 −7 , Fig. S6A ). Our patient-derived HER2 + and TN BBM cells also had increased mRNA copy numbers for ABAT relative to primary breast cancer cell lines (Fig. 3A, Fig. S6B , and Table  S2 ). ABAT protein was expressed by both BBM subtypes in vitro (Fig. 3B) . Tissue specimens revealed greater than twofold increase in ABAT protein expression in the tumor compartments of both HER2 + and TN BBMs relative to primary matched subtype tissues (Fig. 3C and Fig. S6C ). There was no significant difference of ABAT levels in the adjacent brain tissue versus primary stromal compartments for either tumor subtype (Fig. S6C) .
To test whether GABA can act as an energy source to enhance proliferation, BBM cells were incubated with vigabatrin, an irreversible inhibitor of ABAT. Cells were cultured in media containing increasing concentrations of GABA alone or GABA plus 300 μM vigabatrin for 96 h. Vigabatrin abolished the proliferative effect of GABA on BBM cells (Fig. 3D and Fig. S6D ). We determined the intracellular levels of NADH in BBM cells cultured (i) alone, (ii) with 1 μM GABA or muscimol, or (iii) with 1 μM GABA or muscimol and 300 μM vigabatrin. BBM cells cultured in the presence of exogenous GABA produced 47% more intracellular NADH than control (284 pmol versus 193 pmol, respectively), whereas BBM cells cultured with muscimol or exogenous GABA plus vigabatrin did not have elevated NADH levels ( Fig. 3E and Fig. S6E ). These results suggest that GABA is a source of energy that BBM cells can use to fuel proliferation via the GABA shunt.
Glutamate catabolism can also increase NADH levels in the GABAergic environment. Glutamate is decarboxylated by the enzyme GAD67 to produce GABA. GAD67 is specifically expressed in GABAergic neurons and certain peripheral tissues that are also GABA dependent (33) . BBMs have an increase in GAD67 mRNA and protein levels relative to primary breast tumors cells and tissue ( Fig. S7 and Table S2 ). Therefore, BBM cells could use GAD67 to convert glutamate to GABA and thus provide an additional metabolic source to promote tumor cell proliferation.
BBM Cells Express GABAergic Interneuron-Specific Proteins. Parvalbumin, a calcium-binding protein, is an important modulator of GABAergic neuronal synaptic plasticity (34) . Cellular staining revealed that HER2 + and TN BBM subtypes express this protein in vitro (Fig. S8A) . In tissue specimens, parvalbumin expression was significantly increased in the tumor and nontumor compartments of both BBM subtypes, relative to their primary tissue tumor correlates (Fig. S8B) . Collectively, the data indicate that BBMs possess GABAergic characteristics and have a GABA metabolic phenotype. Reelin, a large secreted extracellular matrix glycoprotein, is associated with GABAergic neurons that is crucial for the cytoarchitecture of laminated brain structures (35) . During development, reelin is produced by a subset of neurons called Cajal-Retzius cells and is integral for their migratory capacity (36) . Reelin has also been implicated in the migratory capacity of primary cancer cells (37) (38) (39) . To further characterize GABAergic properties, we determined the expression of reelin in BBM cells relative to primary breast cancer. Staining of tissue specimens showed reelin expression was increased more than sixfold both in HER2 + primary and metastatic tumor cells relative to TN cells ( Fig. 4A and Fig. S9 A and B) . Because reelin and HER2 were coexpressed in the HER2 + tumors, the spatial relationship of these two proteins was examined. We found that 99% of HER2 protein colocalized with reelin in BBM tissue specimens (Fig. 4B) . This was also the case for HER2 + BBM cells in vitro (Fig. S9 C  and D) . TN breast cancer subtypes could have up to 30% of cells with HER2 membrane staining but can still be diagnosed as HER2 negative (40) (41) (42) . Heterogeneity for HER2 expression in TN BBMs was also detected. Within the TN subtype, HER2 positivity was associated with reelin expression, with 99% of HER2 protein colocalizing with reelin ( Fig. S9 C and D) . Three-dimensional renderings from immunofluorescence of tissue and cells further support reelin and HER2 colocalization (Fig. 4C, Fig. S9E , and Movie S1). Reelin and HER2 were coimmunoprecipitated to determine whether there was an interaction between the two proteins. Indeed, coimmunoprecipitates indicated HER2 directly associates with the reelin protein (Fig. 4D) . We generated a 3D structural model of the HER2-reelin complex to identify putative interaction sites (Fig. 4E) . The results suggested aromatic amino acids that form aromatic cages, as well as polar residues that interact electrostatically at the interface between HER2 and reelin ( Fig. 4E and Table S3 ).
Discussion BBM cells were examined for expression of GABA-related variables because GABAergic communication occurs in ∼40% of all synapses in the brain (43) . Despite overexpression of GABA A R mRNA and protein, tumor cell proliferation was not receptor mediated. GABA signaling is known to modulate cell cycle and promote synergistic interactions with glutamate signaling, which could confer a survival advantage (44) . Altered GABA receptor or function could also affect neoplastic cell migration and invasion, which are archetypal features of metastasis (45) . Ultimately, the role of up-regulated GABA A R in BBM cells requires further study.
We next investigated a potential metabolic mechanism underlying enhanced tumor growth by GABA. The results show that uptake of GABA and its subsequent catabolism via the GABA shunt increased NADH levels in the tumor microenvironment, which conferred a proliferative advantage to tumors. GABA is abundant in brain cells and may be functioning as an oncometabolite. Noninvasive clinical metabolic imaging with magnetic resonance spectroscopy in patients has shown the distribution of GABA to be 1 μM/cm 3 in human brain tissue (46) . At this concentration, cultured BBM cells exhibited maximal proliferation. Total GABA levels can range even higher than reported because GABA is present as the precursor for several other molecules found in nervous tissue and cerebrospinal fluid, including GABA-histidine (homocarnosine). Homocarnosine is present exclusively in the brain and cerebrospinal fluid where it functions as an antioxidant and modifies brain excitability (47) . In vivo, homocarnosine can be hydrolyzed by the enzyme homocarnosine/carnosinase synthetase to form GABA and histidine (48) . High levels of GABA are also found in vitro; intracellular levels of GABA in astrocytes can exceed ∼2 mM, and these cells can release ∼700 μM GABA into the brain microenvironment (27) .
BBM cells from the brain microenvironment also display other neuronal-like properties. A strong association was observed between HER2 and reelin, a protein expressed by a subset of GABAergic neurons. It is possible that HER2 and reelin are involved in redundant or convergent pathways that control motility and cytoskeletal shape. The reelin signaling cascade activates phosphatidylinositide 3-kinase (PI3K), which triggers several downstream signaling molecules, including AKT, and results in the activation of actin cytoskeletal proteins (49) . Pathway analysis of Purkinje progenitor cells expressing reelin have identified ENAH/ hMena as a stable gene required for regulating the actin cytoskeleton (50) . Interestingly, hMena is frequently overexpressed in the HER2
+ breast tumor subtype (51) . The colocalization of HER2 with reelin may facilitate the arrangement of HER2 + metastatic cells in the extracellular matrix similar to perineuronal nets that promote synaptic stabilization within the brain microenvironment. Furthermore, HER2 and reelin interaction could enable cooperative modification of the cytoskeleton to promote tumor-stroma interface stability. Through reciprocal interaction from both neoplastic cells and the extracellular matrix, reelin could be responsible for tumor-cell masking to avoid immune surveillance. The cooperation of reelin and HER2 in brain metastases is an area of ongoing investigation in our group. It is unknown whether metastases arise from an aggressive progenitor pool that is present at the primary site early during tumorigenesis or from the dissemination of cells that later adapt to the secondary site to colonize. Our results do not exclude the former but do provide evidence for the latter. The need to understand the biology of metastasis is increasingly relevant as clinical oncology strives for survival gains by preventing advanced stage IV breast cancer. The "seed and soil" hypothesis that frames current investigation of metastasis is uniquely exemplified by the colonization of the brain by circulating breast cancer cells (52) . Accordingly, therapy for brain metastases should use not only cytotoxic approaches against the tumor cell but also perturbation of tumor microenvironment that facilitates cancer cell growth and resilience. We may achieve the essential goal of improving and extending the lives of cancer patients by understanding the dynamic neoplastic ecosystem of brain metastases.
Materials and Methods
Experimental methods are detailed in SI Materials and Methods and include the following: (i) generation of patient-derived tumor lines, (ii) gene expression profiling, (iii) evaluation of patient datasets, (iv) proliferation assay, (v) NAD/NADH measurements, (vi) immunofluorescence staining and quantification, and (vii) computational methods for generating the structural model of HER2-reelin complex.
Data are represented as mean values ± SEM. Statistical significance was assessed using Student t test and one-way ANOVA ± Bonferroni's multiplecomparison test. 
